POTS itself is not associated with mortality. Research on the condition’s natural history describes it plainly: postural tachycardia syndrome does not kill you directly, and many patients improve over time with proper treatment.1PubMed Central. Postural tachycardia syndrome – Diagnosis, physiology, and prognosis That said, calling POTS “not dangerous” misses the larger picture. The condition creates real risks through several indirect pathways, from a sharply elevated suicide risk to complications tied to its overlapping conditions and long-term treatments.
Why POTS Itself Does Not Cause Death
POTS is fundamentally a problem with how your body regulates heart rate and blood flow when you stand up. Your heart races, your blood pressure may fluctuate, and you can feel dizzy, faint, or exhausted. But the heart itself is structurally normal in POTS patients, and the tachycardia is a compensatory response rather than a sign of heart damage. Unlike conditions such as ventricular tachycardia or heart failure, the rapid heartbeat in POTS does not lead to cardiac arrest or organ failure.
This distinction matters because the symptoms of POTS can feel terrifying. A resting-to-standing heart rate jump of 30 beats per minute or more, episodes of near-fainting, chest tightness, and breathlessness can all mimic a cardiac emergency. Many people with POTS end up in emergency rooms convinced something catastrophic is happening. The reassurance that the condition is not lethal on its own is clinically meaningful, but it is not the whole story.
The Disability That POTS Actually Causes
If POTS does not kill you, why does it dominate so many patients’ lives? Because the functional impairment is severe. A study comparing quality-of-life scores found that people with POTS scored significantly worse than healthy populations across physical functioning, role functioning, bodily pain, general health, vitality, and social functioning, with impairment comparable to that reported by patients with other chronic disabling conditions.2Mayo Clinic Proceedings. Quality of Life in Patients With Postural Tachycardia Syndrome In practical terms, many patients struggle to hold jobs, attend school, or maintain social lives.
Research from the UK found that even when compared with patients who have chronic fatigue syndrome and similar levels of fatigue and sleepiness, the overall burden of autonomic symptoms in POTS was still significantly higher.3PubMed Central. Postural tachycardia syndrome is associated with significant symptoms and functional impairment predominantly affecting young women: a UK perspective The condition predominantly affects younger women, many of whom are in their most productive years of education and career building. The gap between how healthy they look to others and how sick they feel is one of the most psychologically damaging aspects of the disease.
Mental Health and Suicide Risk
This is the area where the “POTS isn’t dangerous” framing does real harm. Research has found that people with POTS have significantly more days of poor physical health, fewer days with good energy, more days with activity limitations, worse sleep quality, greater daytime fatigue, and higher pain levels compared with controls. The cumulative weight of those symptoms is associated with a substantially elevated suicide risk. Nearly half of one study’s POTS sample was classified as high risk for suicide.4PubMed. Health-related quality of life and suicide risk in postural tachycardia syndrome
A separate study specifically examined sleep disturbance in POTS patients and found that the proportion of individuals at high risk for suicide was significantly larger among POTS patients than among controls.5PubMed Central. Sleep disturbance linked to suicidal ideation in postural orthostatic tachycardia syndrome Sleep disruption appears to be one driver of that relationship. Chronic insomnia and unrefreshing sleep are among the most common POTS complaints, and poor sleep is a well-established amplifier of suicidal ideation in other chronic conditions too.
So while POTS does not cause death through a cardiac mechanism, the psychiatric burden it creates is a genuine mortality pathway. If you have POTS and are struggling with thoughts of self-harm, that is not a separate problem from your condition. It is part of the condition’s impact, and it deserves the same clinical attention as your heart rate.
Conditions That Travel With POTS
POTS rarely exists in isolation. It tends to cluster with other conditions, and some of those carry their own health risks. Understanding the most common overlaps helps explain why a “benign” diagnosis can still create serious complications.
Hypermobile Ehlers-Danlos Syndrome
Joint hypermobility syndrome and hypermobile Ehlers-Danlos syndrome (hEDS) are among the most frequently observed companions to POTS. In one study of hEDS patients undergoing tilt-table testing, about a third met diagnostic criteria for POTS.6PubMed Central. Hypermobile Ehlers-Danlos Syndrome: Cerebrovascular, Autonomic and Neuropathic Features The connective tissue abnormalities in hEDS are thought to contribute to excessive blood vessel stretching, which worsens blood pooling in the legs and drives the autonomic dysfunction.
The cardiac implications of hypermobility are generally mild. Hypermobile patients may have findings like mitral valve prolapse or slight aortic root dilation, but major structural cardiovascular complications are uncommon.7Journal of Invasive Cardiology. The Prevalence of Cardiac Symptoms in Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder: A Pilot Study The risk from the hEDS-POTS overlap is less about the heart and more about falls, joint injuries from fainting episodes, and chronic pain syndromes that compound disability.
Mast Cell Activation
A significant number of POTS patients also show signs of mast cell activation disorder, a condition where immune cells called mast cells release chemical mediators like histamine and prostaglandins inappropriately. One study found that about 42% of patients initially diagnosed with POTS also had both additional non-orthostatic symptoms (migraines, allergic complaints, skin rashes, gastrointestinal problems) and at least one elevated biochemical marker suggesting mast cell activation.8PubMed Central. Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association
Mast cell activation matters for safety because, at its most severe, it can trigger anaphylaxis or anaphylactoid reactions. Many of the symptoms overlap with POTS itself, including flushing, cramping abdominal pain, diarrhea, and itching, which makes the two conditions easy to confuse and difficult to tease apart clinically.9Autonomic Neuroscience. Mast cell activation and postural tachycardia syndrome If mast cell activation disorder is missed in someone being treated only for POTS, the patient may not receive the antihistamines or mast cell stabilizers that could prevent escalating allergic reactions.
Risks From Treatment Itself
POTS treatment typically starts with lifestyle measures like increased fluid and salt intake, compression garments, and graded exercise. When those are not enough, medications enter the picture. Most of the commonly used drugs, including beta-blockers, midodrine, fludrocortisone, and ivabradine, are well tolerated. A systematic review of ivabradine, for instance, found that it lowered heart rate and relieved symptoms without dropping blood pressure, and side effects like dizziness, nausea, headache, and fatigue usually did not lead patients to stop the medication.10PubMed. Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review
The treatment complication that has caused the most concern in the POTS community is intravenous saline infusion. Some patients whose symptoms do not respond adequately to oral hydration and medication receive periodic or chronic IV fluids, sometimes through a port or peripherally inserted central catheter (PICC line). A study of young patients receiving IV hydration for medication-resistant orthostatic intolerance documented complications including upper extremity deep vein thrombosis in three patients and infection in four.11PubMed. Intravenous Hydration for Management of Medication-Resistant Orthostatic Intolerance in the Adolescent and Young Adult Deep vein thrombosis can potentially progress to a pulmonary embolism, which is life-threatening. Central line infections can become sepsis. These are rare complications, but they are real and have caused deaths in the broader population of patients with long-term vascular access. The decision to place a central line for chronic POTS management is not trivial and should be weighed carefully.
The Misdiagnosis Problem
One of the most dangerous aspects of POTS is not the condition itself but how long it takes to get the right diagnosis. POTS can go unrecognized for years and is frequently mistaken for an anxiety disorder because some of its symptoms, like racing heart, trembling, and a sense of dread, overlap with hyperadrenergic anxiety presentations.12PubMed Central. Postural Orthostatic Tachycardia Syndrome Misdiagnosed as Anxiety: A Case Report with a Review of Therapy and Pathophysiology Patients who are told their symptoms are psychogenic often stop seeking evaluation, delay treatment, and experience worsening mental health from being dismissed.
Meanwhile, the underlying cause may be something that benefits from early identification. POTS has multiple recognized subtypes: neuropathic, hypovolemic, hyperadrenergic, joint-hypermobility-related, and immune-related, with considerable overlap among them.13PubMed. Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management A patient whose POTS stems from small fiber neuropathy needs different management than one whose primary driver is blood volume depletion. The longer diagnosis is delayed, the longer the patient goes without targeted treatment, and the greater the toll on physical and psychological health.
POTS After COVID-19
The COVID-19 pandemic brought a surge of new POTS diagnoses. In a follow-up study of people with long COVID and autonomic dysfunction, roughly 40% were newly diagnosed with POTS after their SARS-CoV-2 infection, representing about a third of the entire long-COVID cohort studied.14PubMed. Chronic autonomic symptom burden in long-COVID: a follow-up cohort study This wave of post-viral POTS has changed the demographics of the condition. Previously, POTS was largely associated with younger women and sometimes with viral illness triggers like mononucleosis. Now, clinicians are seeing it across a wider age range and in more men than before.
Post-viral POTS is not a fundamentally different disease, but it has raised questions about whether outcomes differ depending on the trigger. It is too early for long-term data on post-COVID POTS specifically, but patients whose POTS developed after an infection historically have a reasonable chance of gradual improvement as the immune-mediated process calms down. The concern is that the sheer number of new cases has overwhelmed autonomic specialty clinics, creating long wait times that delay treatment initiation.
Pregnancy With POTS
One of the most common fears among POTS patients of reproductive age is whether pregnancy is safe. The evidence is largely reassuring. A study that followed patients with pre-existing POTS through pregnancy found that POTS symptoms actually improved during pregnancy in the majority of cases, remained unchanged in some, and worsened in a smaller group. All patients completed pregnancy successfully with no stillbirths, and no major complications were attributed to POTS itself.15PubMed. Outcomes of pregnancy in patients with preexisting postural tachycardia syndrome
A broader review of the available literature reached a similar conclusion: complications and adverse events for both mother and infant do not appear to be elevated in women with POTS compared with the general population. The one exception was a possible increased rate of hyperemesis gravidarum (severe pregnancy-related nausea), which may be related to higher migraine prevalence in POTS patients rather than the autonomic dysfunction itself.16PubMed Central. POTS and Pregnancy: A Review of Literature and Recommendations for Evaluation and Treatment The postpartum period warrants monitoring because about a third of patients experienced worsening symptoms after delivery, but the overall message is that POTS is not a contraindication to pregnancy.
What the Long-Term Outlook Looks Like
The trajectory of POTS varies depending on age of onset and underlying cause, but the overall trend leans toward improvement. A study of adolescents and young adults followed over time found that only about 19% reported complete resolution of symptoms at an average of five years after initial treatment. However, an additional 51% reported persistent but improved symptoms, and 16% had only intermittent symptoms. Altogether, roughly 86% of adolescent-onset POTS patients reported resolved, improved, or intermittent symptoms on long-term follow-up.17The Journal of Pediatrics. Outcomes of Adolescent-Onset Postural Orthostatic Tachycardia Syndrome
In younger children and adolescents, the numbers are even more encouraging. One study reported a cumulative symptom-free rate that reached about 48% at one year and climbed to roughly 86% by six years of follow-up.18Frontiers in Pediatrics. Long-Term Outcomes of Children and Adolescents With Postural Tachycardia Syndrome After Conventional Treatment These figures suggest that POTS in younger patients often represents a phase that the body can grow out of, particularly with consistent treatment.
Adults who develop POTS later in life, especially in the setting of autoimmune disease or after a viral trigger, tend to have a more variable course. Some improve substantially, others reach a stable plateau of manageable symptoms, and a smaller group remains severely affected for years. The evidence is thinner for adult-onset cases, partly because large longitudinal studies with long follow-up periods are still lacking for this population.
Fainting, Falls, and Indirect Physical Danger
One practical danger that rarely gets adequate attention in clinical discussions is the risk of injury from syncope or presyncope. POTS patients who faint or come close to fainting while standing are at risk of hitting their head, falling down stairs, collapsing while driving, or dropping to the ground in unsafe environments. These incidents can result in concussions, fractures, or worse. The risk is highest in patients who experience sudden loss of consciousness without adequate warning signs, and in those who have orthostatic hypotension on top of their tachycardia.
Driving deserves specific mention. Many POTS patients can drive safely most of the time, but presyncope at the wheel is a life-threatening situation for the patient and others on the road. Some patients learn to recognize prodromal symptoms and pull over, but the unpredictability of symptom flares means the risk is never zero. Honest self-assessment of driving safety, and a willingness to stop driving during bad flares, is one of the most important practical safety decisions a person with POTS can make.
When POTS Masks Something Else
In rare cases, what looks like POTS turns out to be a secondary presentation of a more dangerous condition. Autoimmune autonomic ganglionopathy, for example, can present with postural tachycardia before progressing to more widespread autonomic failure. Certain tumors, including pheochromocytoma, can cause episodic tachycardia and orthostatic symptoms that mimic POTS. Amyloidosis involving the autonomic nervous system can look like POTS in its early stages. These conditions are uncommon, but they underscore the value of a thorough workup rather than stopping at the POTS label.
The POTS diagnosis is clinical: your heart rate goes up by a defined amount when you stand, you have chronic symptoms, and there is no other obvious explanation like dehydration or medication side effects. Because it is defined by a physiological response rather than a specific underlying disease, POTS can be the visible surface of very different underlying processes. Getting the subtyping right, and ruling out mimics, matters not just for treatment optimization but for catching the rare cases where something more sinister is at work.